Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma

Journal of Gastrointestinal Oncology

Georg Brunauer¹  Nadja Stranzl²  Werner Scheithauer²  Matthias Unseld²  Daniela Bianconi²  Gerald W. Prager²  Christoph C. Zielinski²  Roman Weigl²  Guenther Steger²  Gabriela Kornek² 

[1] Institute for Energy Systems and Thermodynamics, Vienna University of Technology, Vienna, AustriaInstitute for Energy Systems and Thermodynamics, Vienna University of Technology, Vienna, AustriaInstitute for Energy Systems and Thermodynamics, Vienna University of Technology, Vienna, Austria;Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna, 1090 Vienna, AustriaDepartment of Medicine I, Comprehensive Cancer Center, Medical University Vienna, 1090 Vienna, AustriaDepartment of Medicine I, Comprehensive Cancer Center, Medical University Vienna, 1090 Vienna, Austria

关键词: Cholangiocellular carcinoma;    chemotherapy;    second-line treatment;    nab-paclitaxel;    anti-cancer therapy;   

DOI  :  10.21037/jgo.2016.05.01

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown